智通财经APP讯，美中嘉和(02453)发布公告，公司控股股东之一医学之星(上海)企业管理有限公司(上海医学之星)知会公司董事会，上海医学之星于2025年5月7日以每股6.84港元的价格从公开市场购入合共4.56万股公司H股，总对价为31.19万港元，占截至本公告日期公司已发行股份总数约0.01%。此举充分体现上海医学之星对公司未来前景的信心和对公司持续发展的支持。
据上海医学之星告知，其对本集团的业务前景及增长充满信心。在符合适用的法律及监管要求的情况下，上海医学之星不排除会在自本公告日期起六个月内的适当时候通过于公开市场上购买公司额外H股进一步增持公司股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.